Archive for the 'Research Reports' Category
December 31st, 2010 by admin
Novartis has submitted its meningococcal B vaccine Bexsero to the EU for marketing approval. “The Bexsero submission in the EU is an important milestone toward achieving the world’s first broad-coverage MenB vaccine through our unique multi-component approach,” said Andrin Oswald, head of Novartis Vaccines and Diagnostics Division. “Meningococcal disease is sudden and aggressive, leaving little time for treatment. Proactive vaccination of individuals has been shown to offer the best protection against fatal infectious diseases.
Continue reading ‘Novartis Files for Bexsero Approval’
December 14th, 2010 by admin
MedGadget blog tells us about a new dry powder inhaler that, according to Cambridge Consultants and India’s Sun Pharma Advanced Research Company (SPARC), delivers an even drug dose deep into the lungs no matter how strong the patient’s inhalation.
Continue reading ‘Dry Powder Inhaler Stays Strong Even if Breath is Weak’
November 12th, 2010 by admin
Veterans diagnosed with any psychiatric illness appear to have an elevated risk of suicide, and men with bipolar disorder and women with substance abuse disorders may have a particularly high risk, according to the Archives of General Psychiatry.
Continue reading ‘Veterans with Bipolar Disorder May Have Increased Risk of Suicide’
November 11th, 2010 by admin
The FDA’s marathon run toward a new set of regulations to govern the development of biosimilars is official. Regulators will host their first public meeting on follow-on drug regs, and you can expect to hear plenty from big companies like Amgen on the need for lengthy and expensive clinical trials.
Continue reading ‘Amgen Proposes Key Hurdles for Biosimilar Regs’
November 8th, 2010 by admin
Vaccination rates for children insured by commercial plans declined roughly four percentage points between 2008 and 2009. And experts fear that if this trend continues, the public’s health could be jeopardized. ”Rates had been gradually improving in the commercial plans. This was the first time we’d seen a drop–and it was a pretty big drop,” said Sarah Thomas, vice president of public policy and communication for the National Committee for Quality Assurance, which recently released its annual State of Health Care Quality data.
Continue reading ‘Higher Income Parents Forgoing Kids’ Vaccinations’
November 4th, 2010 by admin
Up to a third of U.S. adults could have diabetes by 2050 if Americans continue to gain weight and avoid exercise, said the Centers for Disease Control and Prevention. The numbers are certain to go up as the population gets older, but they will accelerate even more unless Americans change their behavior, the CDC said.
Continue reading ‘Diabetes to Double or Triple in U.S. by 2050′
November 2nd, 2010 by admin
The side effects of the standard medication for Parkinson’s disease have long been a preoccupation of brain researchers. Now Daniella Rylander has presented new findings in a recently defended PhD thesis at Lund University that provide hope of more effective medication for those who suffer from the nerve cell disease.
Continue reading ‘New Parkinson’s Drug Development’
October 22nd, 2010 by admin
The Big 3 drug wholesalers in the U.S.–AmerisourceBergen, McKesson and Cardinal Health–are enjoying a financial boost this year thanks to the growing use of generic drugs. That’s a bus they hope to ride into 2011 and beyond, when they can expect drug distribution’s next big business-shaker: healthcare reform.
Continue reading ‘Drug Wholesalers Enjoy a Financial Boost This Year’
October 14th, 2010 by admin
The Indian pharmaceutical industry has been shaken up lately, worried that multinational drugmakers will come in and completely take over their drug market. The fears aren’t unfounded; Big Pharma, after all, has been targeting the subcontinent as a key location for expansion, as sales-growth slows in the U.S. and Europe.
Continue reading ‘Pharma Protests Indian Licensing Proposal’
October 13th, 2010 by admin
Yes, Star Trek geeks can rejoice. There is now a “cloaking device” for drug delivery. At least, that’s how researchers at the University of Massachusetts Amherst describe what they’re doing. In the current issue of Nature Chemistry, Vincent Rotello says he and his team can deliver a dormant toxin into a specific site such as a tumor for anti-cancer therapy, then chemically trigger the toxin to “de-cloak” and attack the Romul … I mean, tumor, from within.
Continue reading ‘Cloaking Device Boldly Delivers Toxins to Tumor’
